Previous 10 | Next 10 |
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...
Should These Penny Stocks Be On Your Pre What are penny stocks ? Based on the standard definition, we’re talking about stocks under $5. But obviously, there’s more to it than just price, right? Looking for cheap stocks to buy might seem like an easy task. Just find...
Allena Pharmaceuticals (ALNA) soars 44% in premarket on robust volume, in reaction to $25M convertible debt financing agreement with Pontifax Medison Finance.Under the terms of the agreement, Allena will have access to up to $25M in three tranches, which will mature over a four year...
-- Extends Allena’s Cash Runway into 4Q 2021 -- -- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to d...
Allena Pharmaceuticals ( ALNA -1.3% ) has dosed the first patient in a Phase 1 trial of ALLN-346, for the treatment of hyperuricemia (elevated levels of uric acid in the blood) in patients with gout and advanced chronic kidney disease (CKD). More news on: Allena Pharma...
NEWTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...
Allena Pharmaceuticals (NASDAQ: ALNA ) : Q2 GAAP EPS of -$0.26 beats by $0.02 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- -- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 –- -- Raised Gross Proceeds of $22.7M Through Two Public Offerings, Exte...
NEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
News, Short Squeeze, Breakout and More Instantly...
Allena Pharmaceuticals Inc. Company Name:
ALNA Stock Symbol:
NASDAQ Market:
Allena Pharmaceuticals Inc. Website:
Buying Penny Stocks on July 29th? Here’s What You Need to Know If you’re looking for the best penny stocks to buy right now, there are hundreds of options to choose from. As a result, it all comes down to finding the best penny stocks that fit your trading strateg...
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme the...
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...